membran
protein
virus
play
critic
role
viru
life
cycl
attract
target
therapeut
intervent
viruslik
particl
vlp
present
possibl
studi
biochem
biophys
properti
viral
membran
protein
nativ
environ
specif
vlp
construct
contain
entir
protein
sequenc
compris
nativ
membran
compon
includ
lipid
cholesterol
carbohydr
cellular
protein
studi
prepar
vlp
contain
fulllength
hemagglutinin
ha
neuraminidas
na
influenza
character
interact
small
molecul
inhibitor
use
havlp
first
show
vlp
sampl
prepar
use
standard
sucros
gradient
purif
scheme
contain
signific
amount
serum
protein
exhibit
high
potenti
nonspecif
interact
therebi
complic
nmr
studi
ligandtarget
interact
show
serum
contamin
may
larg
remov
addit
gel
filtrat
chromatographi
step
next
use
havlp
demonstr
waterlogsi
nmr
significantli
sensit
satur
transfer
differ
std
nmr
studi
ligand
interact
membran
bound
target
addit
compar
ligand
orient
ha
embed
vlp
recombin
ha
std
nmr
subsequ
step
use
navlp
character
kinet
bind
properti
substrat
analog
inhibitor
na
includ
studi
mutant
lead
wide
spread
resist
current
influenza
antivir
summari
work
suggest
vlp
high
potenti
becom
standard
tool
biochem
biophys
studi
viral
membran
protein
particularli
vlp
highli
purifi
combin
control
vlp
contain
nativ
membran
protein
membran
protein
envelop
virus
includ
ebola
hiv
influenza
sar
coronaviru
play
critic
role
viral
entri
thu
attract
target
antivir
therapeut
kuhn
et
al
lagoja
de
clercq
caffrey
yermolina
et
al
exampl
hemagglutinin
ha
found
viral
membran
influenza
mediat
viru
receptor
bind
entri
neuraminidas
na
also
found
viral
membran
influenza
mediat
viru
egress
skehel
wiley
von
itzstein
studi
viral
membran
protein
biochem
biophys
method
challeng
due
presenc
transmembran
domain
glycosyl
multipl
disulfid
bond
limit
deterg
usag
skehel
wiley
garavito
fergusonmil
von
itzstein
caffrey
date
effort
studi
viral
membran
protein
util
solubil
version
recombin
protein
produc
mammalian
insect
cell
often
requir
addit
stabil
domain
steven
et
al
lee
et
al
li
et
al
julien
et
al
howev
prepar
recombin
construct
tediou
concern
recombin
protein
structur
may
accur
reflect
nativ
structur
due
absenc
transmembran
domain
membran
compon
ie
lipid
carbohydr
cholesterol
cellular
protein
presenc
stabil
domain
altern
approach
prepar
infecti
viru
contain
nativ
membran
protein
howev
clearli
biosafeti
concern
prepar
studi
infecti
viru
eg
pandem
strain
influenza
hiv
ebola
recent
use
viruslik
particl
vlp
becom
power
tool
studi
membran
protein
mani
danger
virus
without
necess
biosafeti
level
facil
yonezawa
et
al
zhang
et
al
garcia
lai
qian
et
al
experi
vlp
prepar
cotransfect
plasmid
encod
desir
viral
membran
protein
plasmid
encod
capsid
background
eg
hiv
influenza
often
addit
report
construct
eg
gfp
luciferas
current
applic
viral
membran
protein
embed
vlp
includ
studi
process
kinet
activ
jacob
et
al
jalagui
et
al
ku
et
al
antanasijev
et
al
tedburi
et
al
drug
screen
trial
kouznetsova
et
al
basu
et
al
use
immunogen
mcburney
et
al
hayn
carra
et
al
nmr
becom
wellestablish
biophys
method
studi
interact
small
druglik
molecul
larger
protein
target
carlomagno
williamson
harner
et
al
exampl
techniqu
satur
transfer
differ
std
waterlogsi
wl
nmr
may
use
character
ligand
bind
atom
level
detail
dalvit
et
al
mayer
meyer
bhunia
et
al
antanasijev
et
al
ramirez
et
al
antanasijev
et
al
case
std
nmr
h
protein
target
select
excit
magnet
transfer
bound
ligand
h
observ
case
wl
nmr
h
water
molecul
select
excit
magnet
transfer
bound
water
h
bound
ligand
h
observ
importantli
std
wl
requir
rel
low
amount
target
protein
lm
enabl
observ
ligand
interact
rel
larg
molecular
weight
biomolecul
readili
identifi
interact
k
rang
mm
pm
recent
std
nmr
appli
studi
interact
small
molecul
influenza
membran
protein
embed
vlp
includ
interact
receptor
analog
ha
embed
vlp
haselhorst
et
al
interact
substrat
inhibitor
analog
na
embed
vlp
mohan
et
al
garcia
et
al
notabl
use
vlp
studi
viral
membran
protein
obviat
potenti
limit
recombin
protein
due
presenc
complet
amino
sequenc
nativ
process
nativ
membran
compon
moreov
std
wl
noebas
method
thu
sensit
increas
increas
molecular
mass
correl
time
williamson
antanasijev
et
al
present
work
show
import
vlp
puriti
studi
viral
membran
protein
use
influenza
ha
na
model
system
moreov
demonstr
wl
significantli
sensit
std
nmr
studi
vlp
interact
addit
compar
interact
inhibitor
membranebound
viral
protein
versu
recombin
protein
final
demonstr
util
vlp
studi
mutant
viral
membran
protein
nmrbase
kinet
method
recombin
ha
product
purif
insect
cell
grown
ii
serum
free
media
life
technolog
cell
cotransfect
plasmid
contain
ha
bei
resourc
express
construct
bd
baculogold
linear
baculoviru
dna
bd
bioscienc
ha
protein
construct
alter
cterminu
transmembran
cytosol
region
protein
remov
replac
artifici
trimer
domain
foldon
fibritin
histag
previous
describ
steven
et
al
cell
handl
transfect
protein
express
perform
recommend
bd
baculogold
starter
packag
kit
bd
bioscienc
viral
titer
monitor
use
bacpak
tm
qpcr
titrat
kit
clontech
laboratori
express
fresh
cell
confluenc
infect
ha
contain
baculoviru
solut
moi
day
later
suspens
collect
cell
remov
centrifug
ha
secret
insect
cell
media
purifi
niaffin
chromatographi
protein
concentr
subject
sephacryl
gel
filtrat
column
phosphat
buffer
mm
sodium
phosphateph
mm
nacl
run
buffer
protein
fraction
pool
concentr
final
yield
mg
ha
per
liter
insect
cell
cultur
cell
grown
dmem
media
fb
penicillinstreptomycin
cell
confluenc
cotransfect
plasmid
encod
hiv
core
nih
aid
reagent
program
ha
strain
bei
resourc
na
strain
apuerto
bei
resourc
product
vlp
na
surfac
navlp
without
viral
membran
protein
nativevlp
cell
cotransfect
hiv
core
na
plasmid
hiv
core
dna
respect
pei
polysci
inc
use
transfect
reagent
h
post
transfect
cell
supernat
collect
ml
clear
lm
filter
concentr
use
amicon
centrifug
filter
unit
millipor
kda
cutoff
concentr
run
sepharos
fast
flow
column
ge
healthcar
phosphat
buffer
mm
sodium
phosphateph
mm
nacl
use
run
buffer
vlp
contain
fraction
combin
subsequ
vlp
precipit
sucros
cushion
rpm
min
vlp
pellet
resuspend
ml
phosphat
buffer
concentr
necessari
dialyz
overnight
phosphat
buffer
remov
residu
sucros
rel
puriti
vlp
fraction
determin
sdspage
novex
bistri
gel
life
technolog
vlp
sampl
lyse
triton
final
concentr
vlp
sampl
without
dilut
load
onto
elisa
plate
precoat
ha
antibodi
manipul
perform
accord
antigen
captur
assay
kit
saic
frederick
hemagglutinin
elisa
develop
kit
immun
technolog
corp
protocol
nmr
experi
perform
bruker
mhz
avanc
spectromet
equip
room
temperatur
cryogen
tripl
reson
probe
respect
wl
experi
perform
previous
describ
antanasijev
et
al
satur
water
h
ms
squar
shape
puls
use
total
satur
time
relax
delay
number
scan
set
correspond
h
experi
satur
transfer
differ
std
experi
perform
previous
describ
antanasijev
et
al
train
ms
gaussian
puls
use
select
excit
protein
h
total
satur
time
relax
delay
set
reson
frequenc
set
ppm
reson
acquisit
set
ppm
total
length
std
experi
h
buffer
condit
mm
phosphateph
mm
nacl
h
wl
h
std
mm
nmr
tube
use
studi
data
process
analyz
use
nmrdraw
delaglio
et
al
rel
std
calcul
describ
previous
mccullough
et
al
briefli
std
std
ob
std
max
std
signal
calcul
base
equat
std
dii
di
reson
intens
presatur
proteinvlp
target
error
std
experi
estim
dii
ref
n
di
di
n
iref
ref
n
di
n
iref
nois
level
calcul
nmrdraw
appropri
spectrum
calcul
rel
std
signal
function
correl
time
target
protein
concentr
use
program
corcemasx
jayalakshmi
krishna
previous
publish
model
complex
antanasijev
et
al
ha
concentr
examin
nm
concentr
ha
vlp
experi
nm
nm
nm
concentr
ha
recombin
ha
experi
lm
ligand
input
paramet
includ
cutoff
distanc
h
k
lm
k
free
ligand
c
ns
mhz
field
strength
satur
time
instantan
irradi
ile
leu
val
methyl
group
na
catalyz
reaction
follow
measur
line
intens
substrat
munana
reson
ppm
experiment
condit
nm
na
vlp
mm
phosphateph
mm
nacl
mm
cacl
presenc
absenc
lm
munana
substrat
originpro
originlab
corp
use
determin
kinet
inhibitori
constant
k
recent
character
interact
small
molecul
inhibitor
influenza
entri
recombin
ha
wl
std
nmr
basu
et
al
fusion
inhibitor
select
j
biomol
nmr
disrupt
entri
group
ha
influenza
virus
like
ha
valu
low
lm
rang
bind
ha
inhibit
critic
ph
depend
conform
chang
antanasijev
et
al
basu
et
al
present
work
want
extend
studi
use
ha
embed
vlp
ascertain
potenti
use
vlp
drug
discoveri
optim
studi
howev
concern
potenti
small
molecul
interact
contamin
present
vlp
prepar
exampl
standard
cell
media
contain
fetal
bovin
serum
fb
result
mg
ml
total
protein
ad
lindl
rel
high
level
ad
protein
could
potenti
form
detect
nonspecif
interact
small
molecul
interest
consequ
first
test
whether
exhibit
bind
protein
present
fb
assay
chose
use
wl
nmr
shown
significantli
sensit
std
nmr
antanasijev
et
al
experi
presenc
posit
phase
signal
small
molecul
presenc
larg
molecular
weight
biomolecul
due
bind
shown
fig
exhibit
detect
bind
serum
protein
level
consequ
rel
puriti
vlp
prepar
potenti
presenc
contamin
solubl
protein
signific
concern
biochem
biophys
studi
next
step
prepar
vlp
contain
ha
use
hiv
core
background
cotransfect
plasmid
contain
ha
hiv
core
previous
describ
antanasijev
et
al
note
prepar
small
amount
plasmid
contain
na
includ
final
protein
ratio
na
ha
enhanc
product
vlp
contain
ha
ha
bind
siallylactos
present
cell
surfac
inhibit
viru
egress
chen
et
al
subsequ
vlp
harvest
collect
cell
supernat
transfect
cell
concentr
use
ultrafiltr
sampl
subject
purif
sucros
gradient
centrifug
standard
protocol
employ
purif
vlp
sampl
use
biochem
biophys
studi
haselhorst
et
al
mohan
et
al
garcia
et
al
analyz
protein
present
sdspage
shown
fig
first
larg
amount
protein
present
start
cell
cultur
media
moreov
vlp
protein
present
initi
purif
step
undetect
point
thu
small
fraction
total
protein
contrast
sucros
gradient
step
vlp
protein
becom
detect
step
howev
remain
rel
small
fraction
total
protein
present
typic
consequ
ad
gel
filtrat
chromatographi
addit
purif
step
shown
fig
viral
protein
becom
predomin
consist
total
protein
thu
prepar
vlp
clearli
appropri
biochem
biophys
biochem
character
use
purif
protocol
concentr
sucros
gradient
centrifug
gel
filtrat
collect
ml
purifi
concentr
stock
ml
start
vlpcontain
supernat
final
prepar
averag
level
ie
hiv
core
fig
wl
nmr
detect
small
molecul
bind
serum
protein
present
cell
cultur
media
refer
nmr
spectrum
downfield
region
shown
arrow
denot
ligand
peak
use
report
ligand
bind
serum
protein
experiment
condit
lm
fetal
bovin
serum
fb
mm
phosphateph
mm
nacl
h
wl
spectra
acquir
h
mhz
spectromet
equip
room
temperatur
probe
lgml
nm
amount
ha
estim
lgml
nm
one
vlp
averag
molecul
jen
et
al
thu
number
calcul
approxim
ha
trimer
per
vlp
na
tetram
good
agreement
literatur
valu
report
differ
type
vlp
hiv
background
rang
viral
membran
protein
per
vlp
crook
et
al
berkow
et
al
zhu
et
al
next
step
purifi
vlp
contain
na
use
control
subsequ
character
membran
embed
na
case
final
concentr
na
lgml
nm
correspond
tetram
na
per
vlp
final
note
rel
number
viral
membran
protein
per
vlp
may
adjust
least
certain
degre
chang
ratio
viral
membran
protein
plasmid
respect
hiv
core
plasmid
wl
nmr
studi
bind
havlp
note
base
studi
recombin
ha
small
molecul
bind
ha
inhibit
influenza
entri
stabil
neutral
ph
conform
antanasijev
et
al
basu
et
al
consequ
test
potenti
detect
bind
ha
embed
membran
use
havlp
wl
nmr
refer
nmr
spectrum
ligand
shown
top
fig
shown
fig
bind
recombin
ha
evid
posit
phase
peak
ligand
presenc
lm
recombin
protein
similar
manner
bind
havlp
clearli
detect
fig
note
specif
bind
ha
establish
perform
control
experi
use
navlp
oppos
havlp
normal
concentr
vlp
fig
control
critic
case
havlp
contain
small
amount
na
note
case
havlp
navlp
experi
concentr
ha
na
nm
shown
fig
sn
similar
ident
experiment
time
use
recombin
ha
vlpbound
ha
despit
fold
decreas
ha
concentr
present
vlp
therebi
demonstr
potenti
high
sensit
vlpbase
nmr
experi
std
nmr
gener
less
sensit
wl
nmr
antanasijev
et
al
howev
std
nmr
offer
uniqu
inform
use
character
orient
ligand
guid
chemic
optim
mayer
meyer
antanasijev
et
al
thu
test
potenti
character
bind
ha
embed
membran
ie
havlp
std
nmr
shown
fig
bind
havlp
clearli
detect
std
nmr
importantli
detect
bind
observ
navlp
case
vlp
concentr
normal
use
next
quantifi
rel
intens
ligand
h
reflect
rel
proxim
ligand
h
ha
surfac
mayer
meyer
bhunia
et
al
antanasijev
et
al
basu
et
al
fig
compar
rel
orient
membran
bound
ha
rel
orient
recombin
ha
note
recombin
ha
experi
perform
lm
havlp
experi
perform
nm
strikingli
rel
proxim
ligand
h
similar
suggest
mode
bind
similar
recombin
membran
bound
ha
exampl
aromat
region
molecul
closer
contact
hydrophob
residu
bind
pocket
involv
bind
azepan
moieti
accordingli
linker
azepan
group
may
repres
attract
region
introduc
chemic
chang
improv
inhibitori
pharmacokinet
properti
compound
mention
observ
similar
std
signal
recombin
ha
lm
vlpbound
ha
nm
next
step
use
program
corcema
jayalakshmi
krishna
previous
publish
model
complex
antanasijev
et
al
calcul
rel
std
signal
function
correl
time
target
protein
concentr
fig
base
estim
correl
time
recombin
ha
trimer
ns
rel
std
signal
expect
fig
hand
estim
correl
time
vlpbound
ha
estim
ms
rel
std
signal
expect
fig
thu
observ
similar
std
signal
ha
differ
physic
state
rel
good
agreement
corcema
simul
summari
std
nmr
studi
perform
vlp
base
sampl
suggest
mode
bind
ha
similar
recombin
membran
bound
form
importantli
havlp
provid
type
qualiti
inform
recombin
ha
base
experi
use
significantli
less
materi
current
treatment
influenza
includ
inhal
zanamivir
relenza
oral
oseltamivir
tamiflu
intraven
peramivir
rapivab
develop
substrat
analog
target
viral
na
von
itzstein
et
al
lagoja
de
clercq
cairo
previou
studi
shown
navlp
purifi
use
sucros
gradient
centrifug
exhibit
enzymat
activ
mohan
et
al
garcia
et
al
accordingli
test
whether
navlp
purifi
addit
gel
filtrat
step
discuss
fig
suitabl
kinet
biophys
studi
first
use
acid
munana
fluoresc
substrat
analog
na
potier
et
al
measur
activ
na
present
navlp
nmr
detect
product
format
shown
fig
product
uniqu
form
presenc
navlp
enzym
activ
revers
addit
inhibitor
dana
transit
state
analog
parent
compound
fdaapprov
na
inhibitor
von
itzstein
et
al
lagoja
de
clercq
cairo
importantli
control
measur
use
vlp
prepar
absenc
na
express
nativevlp
level
use
normal
amount
vlp
sampl
exhibit
activ
fig
shown
fig
michaelismenten
plot
vlpbound
na
activ
yield
k
lm
good
welti
et
al
collin
et
al
marath
et
al
support
function
vlpbound
na
next
step
prepar
na
possess
mutat
respons
resist
tamiflu
bloom
et
al
mckimmbreschkin
shown
fig
michaelismenton
plot
vlpbound
activ
yield
k
lm
good
agreement
previou
fluorescencebas
kinet
studi
tamiflu
resist
mutant
bloom
et
al
mckimmbreschkin
support
potenti
nmr
kinet
studi
na
mutat
navlp
next
step
wl
nmr
appli
detect
interact
inhibitor
dana
navlp
control
measur
use
amount
vlp
prepar
absenc
na
express
nativevlp
level
use
normal
amount
vlp
sampl
shown
fig
bind
dana
navlp
easili
detect
wl
nmr
importantli
dana
bind
naspecif
shown
absenc
signal
nativevlp
compar
amount
wl
signal
navlp
experi
absenc
presenc
mm
munana
substrat
analog
use
wl
nmr
competit
assay
previous
develop
recombin
protein
group
antanasijev
et
al
basu
et
al
shown
fig
presenc
substrat
high
excess
caus
decreas
dana
wl
signal
consist
competit
inhibit
model
previous
describ
famili
compound
meindl
et
al
work
demonstr
high
potenti
use
vlpbase
system
studi
viral
membran
protein
nmr
method
model
system
chose
vlp
prepar
influenza
protein
ha
na
surfac
potenti
target
novel
antivir
hiv
core
hiv
core
use
allow
express
vlp
differ
combin
viral
membran
protein
well
vlp
contain
nativ
protein
host
cell
jacob
et
al
yermolina
et
al
antanasijev
et
al
antanasijev
et
al
importantli
nativevlp
offer
potenti
serv
power
control
sampl
demonstr
specif
small
molecul
interact
membran
bound
target
knowledg
previou
biochem
biophys
studi
vlp
util
nativevlp
control
haselhorst
et
al
mohan
et
al
garcia
et
al
studi
ha
embed
vlp
character
ha
interact
small
molecul
antivir
bind
ha
stem
loop
region
prevent
critic
chang
conform
antanasijev
et
al
b
basu
et
al
howev
nonspecif
bind
ligand
target
biomolecul
may
due
promiscu
ligand
andor
target
signific
concern
ligand
base
nmr
techniqu
consequ
first
test
import
vlp
puriti
reduct
nonspecif
interact
test
bind
protein
present
fb
routin
addit
cell
cultur
potenti
contamin
due
high
protein
concentr
exampl
fb
contain
mgml
total
protein
lindl
purif
scheme
serum
protein
would
remov
would
still
contain
lgml
compar
target
fig
nonspecif
interact
protein
present
fb
inde
observ
therefor
made
effort
purifi
vlp
prepar
serum
protein
well
cellular
compon
histor
sucros
gradient
centrifug
primari
method
concentr
purifi
virus
vlp
use
biochem
biophys
studi
haselhorst
et
al
mohan
et
al
garcia
et
al
present
work
show
treatment
alon
enough
achiev
accept
level
puriti
requir
nmr
studi
fig
inde
sucros
gradient
centrifug
step
viral
protein
account
total
protein
present
howev
combin
sucros
gradient
centrifug
gel
filtrat
help
remov
major
serum
well
cellular
protein
sampl
viral
protein
account
total
protein
content
purifi
vlp
prepar
qualiti
may
improv
applic
addit
step
eg
ion
exchang
affin
chromatographi
howev
addit
step
expect
result
loss
vlp
amount
activ
moreov
mani
remain
protein
present
vlp
expect
due
nativ
membran
vlp
form
thu
alway
remain
importantli
activ
remain
nativ
protein
may
account
prepar
nativevlp
fig
altern
vlp
contain
anoth
membran
protein
fig
discuss
demonstr
util
addit
purif
step
character
interact
ha
embed
vlp
correspond
full
length
ha
contain
nativ
ctermin
transmembran
intracellular
domain
wl
nmr
interestingli
significantli
greater
size
vlp
particl
mda
compar
recombin
ha
kda
result
much
higher
sensit
experi
perform
vlp
exampl
nm
ha
embed
vlp
necessari
obtain
wl
nmr
spectra
optim
sn
ratio
h
experi
order
collect
data
compar
qualiti
ie
sn
recombin
ha
target
lm
concentr
necessari
consequ
switch
recombin
viral
membran
protein
without
transmembran
domain
ha
embed
vlp
time
sensit
observ
support
high
sensit
wl
nmr
larg
biomolecular
system
antanasijev
et
al
furthermor
note
control
version
vlp
readili
gener
exampl
exhibit
nondetect
interact
navlp
fig
strongli
support
specif
compound
ha
context
membran
environ
next
step
compar
bind
mode
recombin
ha
ha
embed
vlp
std
nmr
fig
character
inhibitor
dana
bind
navlp
nmr
wl
nmr
spectra
dana
bind
navlp
middl
spectrum
nativ
vlp
bottom
spectrum
refer
nmr
spectrum
dana
shown
top
spectrum
b
wl
nmr
competit
assay
demonstr
competit
bind
inhibitor
dana
substrat
analog
munana
experiment
condit
wl
nmr
nm
na
vlp
lm
dana
mm
munana
mm
po
ph
mm
nacl
wl
spectra
acquir
h
mhz
spectromet
equip
cryogen
probe
fig
note
std
nmr
give
insight
rel
contact
ligand
h
target
surfac
thu
may
exploit
guid
chemic
optim
agreement
previou
work
antanasijev
et
al
observ
std
nmr
significantli
less
sensit
wl
nmr
wl
std
spectra
acquir
h
respect
nonetheless
similarli
wl
studi
achiev
increas
sensit
factor
perform
experi
havlp
respect
recombin
ha
show
good
agreement
corcema
simul
fig
strikingli
recombin
ha
havlp
dataset
gave
almost
ident
std
signatur
fig
suggest
similar
bind
mode
case
rel
low
std
signal
h
linker
region
azepan
group
suggest
attract
site
chemic
optim
compound
final
absenc
measur
std
signal
control
measur
navlp
confirm
specif
toward
ha
importantli
knowledg
work
repres
first
comparison
bind
mode
small
molecul
inhibitor
recombin
membranebound
version
membran
protein
next
demonstr
util
vlp
appli
na
high
prioriti
target
influenza
antivir
von
itzstein
et
al
lagoja
de
clercq
cairo
first
step
show
na
embed
vlp
exhibit
specif
enzym
activ
activ
inhibit
dana
fig
parent
compound
current
influenza
antivir
von
itzstein
et
al
lagoja
de
clercq
cairo
subsequ
full
analysi
na
activ
inhibit
perform
nmr
fig
addit
demonstr
abil
character
mutant
na
commonli
occur
mutat
respons
resist
tamiflu
bloom
et
al
mckimmbreschkin
notabl
vlp
exhibit
k
increas
good
agreement
previou
studi
recombin
influenza
viru
na
k
mutant
rang
higher
wildtyp
rameixwelti
et
al
collin
et
al
note
respect
recombin
membran
protein
mutat
readili
gener
vlp
caffrey
yermolina
et
al
antanasijev
et
al
exampl
product
mutant
recombin
protein
mammalian
insect
express
system
requir
week
effort
oppos
vlp
routin
produc
day
final
demonstr
util
vlp
biophys
studi
character
interact
inhibitor
dana
navlp
wl
nmr
shown
fig
observ
bind
dana
navlp
nativevlp
underscor
import
nativevlp
control
addit
perform
competit
wl
nmr
assay
demonstr
dana
competit
inhibitor
na
substrat
previous
observ
structur
kinet
studi
thu
clearli
show
vlp
use
combin
nmr
detect
bind
differ
inhibitor
well
bind
site
type
inhibit
summari
work
suggest
vlp
high
potenti
becom
standard
tool
biochem
biophys
studi
viral
membran
protein
particularli
highli
purifi
combin
control
vlp
contain
nativ
membran
importantli
vlp
construct
contain
entir
protein
sequenc
compris
nativ
membran
compon
includ
lipid
cholesterol
carbohydr
cellular
protein
date
biochem
biophys
studi
limit
viral
membran
protein
influenza
haselhorst
et
al
mohan
et
al
garcia
et
al
work
report
herein
howev
vlp
contain
mani
viral
membran
protein
includ
ebola
hiv
sarscov
readili
gener
virolog
studi
jacob
et
al
kuhn
et
al
yermolina
et
al
thu
confid
system
also
amen
studi
biochem
biophys
method
discov
character
optim
ligand
interact
